Interviews

In patients with heart failure and diabetes, sotagliflozin can lower glucose quite well, even when patients are facing suboptimal glomerular filtration rates, noted Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School.

Both REDUCE-IT and STRENGTH recruited people with very high triglycerides and tested different formulations of omega-3 fatty acids, but the results were different. About 12% of the difference can be explained, noted Børge G. Nordestgaard, MD, DMSc, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, but 13% cannot be, given that REDUCE-IT had a 25% reduced risk of atherosclerotic cardiovascular disease.

There was a reduction in both the need for dialysis and progression to end-stage renal disease; finerenone was really well tolerated, stated Bertram Pitt, MD, professor of medicine emeritus, University of Michigan School of Medicine.

With finerenone being a targeted therapy, data show there may be an additive cardiorenal benefit when it is coadministered with a sodium glucose co-transporter 2 inhibitor, noted Dipti Itchhaporia, MD, FACC, FAHA, FESC, president of the American College of Cardiology.

Whatever your theory of heart failure with preserved ejection fraction, sodium glucose co-transporter 2 (SGLT2) inhibitors seem to be attacking every one, noted Javed Butler, MD, MPH, MBA, University of Mississippi.

Sodium glucose co-transporter 2 (SGLT2) inhibitor use in patients with heart failure with preserved ejection fraction (HFpEF) has generated great enthusiasm, noted Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the anticipation for more biosimilars to enter the oncology market and the current level of interest in the pipeline.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.

The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.

There are incredible data for sodium-glucose co-transporter 2 (SGLT2) inhibitors, and this is a great class of medicines that is vastly underutilized, stated Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School.

Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, dispels common misconceptions involving eating disorders among patients with type 1 diabetes.

There will be new ESC heart failure guidelines and presentation of data from EMPEROR-Preserved and EMPEROR-Pooled, noted Rudolf de Boer, MD, PhD, of University Medical Center Groningen, the Netherlands.

On this episode of Managed Care Cast, Laalitha Surapaneni, MD, MPH, an assistant professor of medicine at the University of Minnesota, describes her work in bringing awareness to the health impacts of climate change.

Krajowe Centrum ds AIDS (National AIDS Center) in Warsaw, Poland, was founded in 1993 as part of the country’s Ministry of Health. Its chief area of advocacy and outreach is access to antiretroviral treatment, in addition to new areas of focus that include prevention of sexually transmitted infections and hepatitis C virus.

There are several biomarkers that act as therapeutic targets for asthma, and plenty of medications aimed at inhibiting them, according to William "Andy" Nish, MD.

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, discusses the potential for biosimilar utilization to grow and the reasons why his practice favors them over reference products.

Actinic keratosis outcomes can be affected by several variables, and these lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS) was founded on April 10, 1992, just 3 years after the fall of communism, making it the first such organization in the country following a time when HIV was not officially acknowledged nor prevention of HIV and sexually transmitted infections discussed.

Mary Pat Gallagher, MD, of NYU Langone Health, outlines why young individuals should be vaccinated against COVID-19 and Finnish data on increased rates of type 1 diabetes (T1D) seen during the pandemic.

Catlin Dennis, MPH, explains the importance of securing internet and technology access among vulnerable youth with diabetes.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, speaks on the impact of screen usage for eyes and trends in eye symptom burden reported amid the pandemic.

Bobeck Modjtahedi, MD, elaborates on the importance of devising effective and convenient mechanisms for diabetic retinopathy screening.

Dawn Averitt opened the session, “Refocus on HIV: How Innovation in HIV Will Address Individual Patient Needs,” on day 1 of IAS 2021, this year's virtual annual meeting of the International AIDS Society, which took place July 18-21.

We can safely delay excising in situ and early-stage melanomas while managing our patients’ care, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Camillo Ricordi, MD, FNAI, outlines the current status of islet transplantation for patients with type 1 diabetes in the United States.

Getting vaccinated is important to protect yourself, your family, and your community, says William "Andy" Nish, MD, an allergist and immunologist at Northeast Georgia Physicians Group.

Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, talks about the importance of conducting regular evaluations to ensure that prescribing the most cost-effective option, whether that be a biosimilar or the reference product.

Collaborating with colleagues outside of dermatology helps to maximize the chances of skin cancer not coming back, especially in rare cases of noncontiguous tumors, noted Rajiv Nijhawan, MD, director of the UTSW High Risk Skin Cancer Transplant Clinic, in Dallas, Texas.

Hilary Babcock, MD, MPH, infectious disease specialist at Washington University and BJC Healthcare in St. Louis, Missouri, discusses the effectiveness of COVID-19 vaccination against the delta variant and the low likelihood of breakthrough infection.

SisterLove Inc is a 32-year-old sexual reproductive health rights and justice organization with a core focus on HIV and sexually transmitted infections at the intersection of other challenges to women's sexual reproductive health and well-being.